<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FLURAZEPAM HYDROCHLORIDE</span><br/>(flure-az'e-pam)<br/><span class="topboxtradename">Apo-Flurazepam <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Dalmane, </span><span class="topboxtradename">Durapam, </span><span class="topboxtradename">Novoflupam <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">anxiolytic</span>; <span class="classification">sedative-hypnotic</span>; <span class="classification">benzodiazepine</span><br/><b>Prototype: </b>Lorazepam<br/><b>Pregnancy Category: </b>X<br/><b>Controlled Substance: </b>Schedule IV<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>15 mg, 30 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Benzodiazepine derivative, with hypnotic activity equal to or greater than that produced by barbiturates or chloral hydrate.
         Mode and site of action not known; appears to act at limbic and subcortical levels of CNS to produce sedation, skeletal muscle
         relaxation, and anticonvulsant effects.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reduces sleep induction time; produces marked reduction of stage 4 sleep (deepest sleep stage) while at the same time increasing
         duration of total sleep time.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Hypnotic in management of all kinds of insomnia (e.g., difficulty in falling asleep, frequent nocturnal awakening or early
         morning awakening or both). Also for treatment of poor sleeping habits.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Prolonged administration; sleep apnea; intermittent porphyria; acute narrow-angle glaucoma; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired renal or hepatic function; mental depression, psychoses, history of suicidal tendencies, addiction-prone individuals;
         older adult or debilitated patients; COPD.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Sedative, Hypnotic</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> <i><img src="../images/special/greaterorequal.gif"/>15 y,</i> 1530 mg h.s.<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> 15 mg h.s.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give once patient is in bed and ready to fall asleep.</li>
<li>Store in light-resistant container with childproof cap at 15°30° C (59°86° F) unless otherwise
            specified.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> <span class="speceff-common">Residual sedation, drowsiness,</span> light-headedness, dizziness, ataxia, headache, nervousness, apprehension, talkativeness, irritability, depression, hallucinations,
      nightmares, confusion, paradoxic reactions: excitement, euphoria, hyperactivity, disorientation, <span class="speceff-life">coma</span> (overdosage). <span class="typehead">Special Senses:</span> Blurred vision, burning eyes. <span class="typehead">GI:</span> Heartburn, nausea, vomiting, diarrhea, abdominal pain. <span class="typehead">Body as a Whole:</span> Immediate allergic reaction, hypotension, granulocytopenia (rare), jaundice (rare). 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Flurazepam may increase serum levels of <span class="alt">total and direct bilirubin,</span> <span class="alt">alkaline phosphatase,</span> <span class="alt">AST,</span> and <span class="alt">ALT.</span> False-negative <span class="alt">urine glucose</span> reactions may occur with <span class="alt">Clinistix</span> and <span class="alt">Diastix;</span> no effect with <span class="alt">TesTape.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Alcohol</b>, <span class="classification">cns depressants</span>, <span class="classification">anticonvulsants</span> potentiate CNS depression; <b>cimetidine,</b> <b>disulfiram</b> may increase flurazepam levels, thus increasing its toxicity. <span class="typehead">Herbal:</span> <b>Kava-kava,</b> <b>valerian</b> may potentiate sedation. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> 1545 min. <span class="typehead">Duration:</span> 78 h. <span class="typehead">Distribution:</span> Crosses bloodbrain barrier and placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver to active metabolites. <span class="typehead">Elimination:</span> Excreted primarily in urine. <span class="typehead">Half-Life:</span> 47100 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor effectiveness. Hypnotic effect is apparent on second or third night of consecutive use and continues 12 nights
            after drug is stopped (drug has a long half-life).
         </li>
<li>Supervise ambulation. Residual sedation and drowsiness are relatively common. Excessive drowsiness, ataxia, vertigo, and falling
            occur more frequently in older adults or debilitated patients.
         </li>
<li>Monitor drug ingestion if patient has a history of drug abuse. Prolonged use of large doses can result in psychic and physical
            dependence.
         </li>
<li>Lab tests: Obtain blood counts and liver and kidney function with repeated use.</li>
<li>Be aware that withdrawal symptoms have occurred 3 d after abrupt discontinuation after prolonged use and include worsening
            of insomnia, dizziness, blurred vision, anorexia, GI upset, nasal congestion, paresthesias.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Avoid potentially hazardous activities until response to drug is known.</li>
<li>Avoid alcohol. Concurrent ingestion with flurazepam intensifies CNS depressant effects; symptoms may occur even when alcohol
            is ingested as long as 10 h after last flurazepam dose.
         </li>
<li>Be aware of the possible additive depressant effects when drug is combined with barbiturates, tranquilizers, or other CNS
            depressants.
         </li>
<li>Do not change dose intervals or dosage. Do not take for a self-diagnosed problem.</li>
<li>Ask physician about the desirability of discontinuing the drug if you become or intend to become pregnant during therapy.</li>
<li> 							Note: Prolonged use of this hypnotic is inadvisable because insomnia is usually transient. 						</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>